Skip to main content
In stock|Immunotherapy (Investigational)

Magrolimab

Oncology TypeHematologic
Drug Class / MechanismCD47 (Macrophage Checkpoint) Inhibitor
No Image
Description

Magrolimab is classified as a CD47 (Macrophage Checkpoint) Inhibitor, sourced for use within our Immunotherapy (Investigational) portfolio. Reach out to our team for full regulatory documentation, pricing, and current availability.

Therapeutic CategoryImmunotherapy (Investigational)
Oncology TypeHematologic

Send Inquiry

Submit your details to get a formal quote for this product.

Step 1 of 3